COLL vs LLY · P/E 17, rev $181.9M vs P/E 39, rev $65.18B
Collegium Pharmaceutical Inc (COLL) versus Eli Lilly and Company (LLY) — a side-by-side from cached financials, not a winner call.
Collegium Pharmaceutical Inc (COLL) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David Ricks.
Latest reported COLL revenue for 2024-12-31 was $181.9M. Net income was $69.2M. Revenue was up 14.2% from 2024-09-30 to 2024-12-31. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
Latest reported LLY revenue for 2025-12-31 was $65.18B. Net income was $20.64B. Revenue was up 44.7% from 2024-12-31 to 2025-12-31. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
COLL currently screens at market cap $1.12B and trailing P/E 16.8. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
Not investment advice. Open the COLL and LLY stock pages for the full models.
Not investment advice.